Study Identifies Risk Factors for Infliximab Discontinuation in RA - The Center for Biosimilars

Study Identifies Risk Factors for Infliximab Discontinuation in RA  The Center for Biosimilars

A study presented at the recent ISPOR 2019 meeting assessed both the cost associated with treatment with infliximab for patients at US hospitals as well as ...